CN1418673A - Method for extracting coxtex mouten total glucoside for treating hepatitis - Google Patents
Method for extracting coxtex mouten total glucoside for treating hepatitis Download PDFInfo
- Publication number
- CN1418673A CN1418673A CN 02138687 CN02138687A CN1418673A CN 1418673 A CN1418673 A CN 1418673A CN 02138687 CN02138687 CN 02138687 CN 02138687 A CN02138687 A CN 02138687A CN 1418673 A CN1418673 A CN 1418673A
- Authority
- CN
- China
- Prior art keywords
- cortex moutan
- ethanol
- ethyl acetate
- ethyl alcohol
- extracting method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The extraction method of moutan bark total glycoside for curing hepatitis includes the following steps: pulverizing dried moutan bark to obtain coarse powder, soaking in ethyl alcohol and making percolation to obtain percolate, making the percolate undergo the process of reduced pressure distillation to recover ethyl alcohol, adding ethyl acetate-ethyl alcohol mixture liquid to make extraction, taking out supernatant fluid and using reduced pressure distillation method to recover ethyl acetate-ethyl alcohol, concentrating to obtain thick-paste material, the vacuum drying so as to obtain moutan bark total glycoside paste in whith the total glycoside content is above 50%. It possesses the obvious functions of protecting liver, reducing transminase, preventing fibrosis of chronic hepatitis and improving pathologic change of liver cell, etc.
Description
Technical field: the present invention relates to a kind of biochemical drug technology of preparing, particularly a kind of extracting method that is used for the treatment of the Cortex Moutan total glycosides of hepatitis.
Background technology: Cortex Moutan, another name Cortex Moutan, unpeeled CORTEX MOUTAN, wooden Radix Paeoniae, bar Cortex Moutan, Luoyang flower.It is the root bark of Ranunculaceae Radix Paeoniae tail plant Paeonia suffruticosa.Acrid in the mouth, hardship, cold in nature.Go into the heart, liver, kidney three warps.Function with clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling is a Chinese herbal medicine commonly used.Modern medicine studies show that: Cortex Moutan contains peoniflorin, paeonol glucose galactoside, and contains paeonol; In addition, also contain multiple components such as benzoic acid, volatile oil, saccharide and sterol.But the paeonol that adopts physical method to extract at present only is a kind of composition in the Cortex Moutan.Because the composition that extracts is single, has both caused the waste of other compositions in the crude drug, has influenced the crude drug pharmaceutical value again and excavated and development and use comprehensively.
Summary of the invention: technical problem to be solved by this invention is: a kind of fundamental component that can either keep substantially in the crude drug is provided, can excavates comprehensively and develop the extracting method of the Cortex Moutan total glycosides that is used for the treatment of the hepatitis class of its pharmaceutical value again.Its technical scheme is: a kind of extracting method that is used for the treatment of the Cortex Moutan total glycosides of hepatitis class is characterized in that its method step:
A, exsiccant Cortex Moutan is broken into coarse powder, soak percolation with 3-5 ethanol doubly;
B, the percolate that obtains is reclaimed ethanol with distillation under vacuum, Cortex Moutan extractum;
C, get Cortex Moutan extractum, add the ethyl acetate-ethanol mixed liquor in 1: 1 ratio and extract, after the solution layering, get the solution on upper strata;
D, the upper solution of taking out is reclaimed ethyl acetate-ethanol reagent with distillation under vacuum, and be concentrated into thick paste;
E, under 740mmHG, carry out vacuum drying when temperature is 50-60 ℃, Cortex Moutan total glycosides cream.
Through the Cortex Moutan total glycosides cream powder that this method is extracted, through HPLC and Cortex Moutan contrast, both chromatographic peak basically identicals (seeing Appendix 1) illustrate that the Cortex Moutan total glycosides that this method is extracted has kept the fundamental component in the crude drug substantially; And measure and total glycoside mensuration through HPLC, its total glycosides content is crossed 50% (seeing Appendix 2).By antiinflammatory action to chemical liver injury, immunologic liver injury, immunity Liver Fibrosis Model and function of gallbladder promoting experimental model research Cortex Moutan total glycosides, and inquired into the part mechanism of Cortex Moutan total glycosides antiinflammatory action from influencing aspects such as immune antioxidation, the result shows:
1, Cortex Moutan total glycosides 25,50,100mgKG
-1Continuous once a day 7 days of ig administration has obvious effect to carbon tetrachloride (CCl) and the inductive mice chemical liver injury of D-breast enlargement osamine salt (D-Gal-N), the ALT and the AST of rising are reduced, and can obviously resist the reduction of glutathion peroxidase (GSHpx) in liver homogenate due to CCl and the D-Gal-N and the serum, obviously alleviate mouse liver cell degeneration, necrosis and cell infiltration.
2, Cortex Moutan total glycosides 25,50,100mgKG
-1Continuous once a day 9 days of ig administration, bacillus calmette-guerin vaccine (BCG) is added the inductive mouse immune liver damage of lipopolysaccharide (LPS) obvious effect is arranged, not only can significantly reduce BCG and add inductive ALT of LPS and AST rising, obviously alleviate the hepatic pathology infringement, and the serum of rising and hepatic tissue malonaldehyde are obviously reduced.
3, due to human serum albumin (HAS) the chronic immunity rat liver fibrosis discover Cortex Moutan total glycosides 50,100mgKG
-1Ig prevention and treatment administration in continuous once a day 8 weeks, all can make serum sialic acid (SA) level of rising and liver hydroxyproline (HyP) level obviously reduce, and Fibrotic pathological lesion had obviously alleviate trend.
4, immunology studies show that: continuous once a day 7 days of Cortex Moutan total glycosides 25,50,100mgKGig administration, the minimizing that caused by cyclophosphamide mice hemolytic antibody is produced and the reduction of spleen index and the tardy paraphilia reaction of mice tangible antagonism lowly all arranged, but also obviously strengthen the index of cleaning up of mouse monokaryon macrophage; In vitro study is found, Cortex Moutan total glycosides 2-50mgL
-1Regulating bone-marrow-derived lymphocyte breeder reaction under the mice, rat abdominal cavity macrophage interleukin 1 (IL-1) and rat spleen cells IL-2 produces.
5, Cortex Moutan total glycosides 50,100mgKG
-1Continuous once a day 7 days of ig administration does not have obvious influence to the content of the bile flow of rat and total bilirubin, cholesterol, bile acid.
In sum, in vivo and in vitro in the zoopery, the Cortex Moutan total glycosides that extracts through this method has tangible the liver protecting and ALT lowering, prevents and treats hepatic fibrosis, improves the variation of hepatocyte pathology, antioxidation and immunoregulation effect, for its clinical trial and clinical practice from now on provide important pharmacology's foundation.
Embodiment:
Getting exsiccant 100kg Cortex Moutan and break into coarse powder, is the soak with ethanol of 30-70% percolation after 24 hours with the concentration of 400kg, accesses percolate.
With the percolate that obtains, reclaim ethanol reagent with distillation under vacuum.Specific requirement is: the 400mmHG that reduces pressure, in water-bath, heat, and no ethanol flavor obtains Cortex Moutan extractum this moment in recovered solvent.
Get Cortex Moutan extractum, add the ethyl acetate-ethanol mixed liquor in 1: 1 ratio of volume and extract.The ratio of ethyl acetate-ethanol mixed liquor is 2: 1.After the solution layering, get the solution on upper strata.
The upper solution of taking out is reclaimed ethyl acetate-ethanol reagent with distillation under vacuum, and specific requirement is: the 400mmHg that reduces pressure heats in water-bath, up to being condensed into thick paste.
Under 740mmHg, when temperature is 50-60 ℃, carry out vacuum drying, get Cortex Moutan total glycosides cream.
Get Cortex Moutan total glycosides cream powder after the taking-up dried cream powder is broken.This product is a yellow powder, easily moisture absorption, and paste-forming rate is about 3%, and the content of total glycosides has surpassed 50%.
After dried cream powder adds different auxiliary materials and mixing, can make various dosage forms such as capsule, tablet, granule, syrup.
Claims (4)
1, a kind of extracting method that is used for the treatment of the Cortex Moutan total glycosides of hepatitis class is characterized in that its method step:
A, exsiccant Cortex Moutan is broken into coarse powder, soak percolation with 3-5 ethanol doubly;
B, the percolate that obtains is reclaimed ethanol with distillation under vacuum, Cortex Moutan extractum;
C, get Cortex Moutan extractum, add the ethyl acetate-ethanol mixed liquor in 1: 1 ratio and extract, after the solution layering, get the solution on upper strata;
D, the upper solution of taking out is reclaimed ethyl acetate-ethanol reagent and is concentrated into thick paste with distillation under vacuum;
E, under 740mmHG, carry out vacuum drying when temperature is 50-60 ℃, Cortex Moutan total glycosides cream.
2, as weighing 1 described a kind of extracting method, it is characterized in that: described concentration of ethanol is 30-70%.
3, as weighing 1 described a kind of extracting method, it is characterized in that: described ethyl acetate mixed liquor, its ratio are 2: 1.
4, as weighing 1 described a kind of extracting method, it is characterized in that: described distillation under vacuum reclaims ethanol and ethyl acetate-ethanol reagent, and its specific requirement is: the 400mmHg that reduces pressure distills in water-bath.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021386870A CN1187069C (en) | 2002-11-26 | 2002-11-26 | Method for extracting coxtex mouten total glucoside for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021386870A CN1187069C (en) | 2002-11-26 | 2002-11-26 | Method for extracting coxtex mouten total glucoside for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1418673A true CN1418673A (en) | 2003-05-21 |
| CN1187069C CN1187069C (en) | 2005-02-02 |
Family
ID=4749631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021386870A Expired - Fee Related CN1187069C (en) | 2002-11-26 | 2002-11-26 | Method for extracting coxtex mouten total glucoside for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1187069C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367986C (en) * | 2006-08-17 | 2008-02-13 | 陈乃车 | Cooperative drug comprising biphenyldicarboxylate |
| CN100421688C (en) * | 2006-07-04 | 2008-10-01 | 刘海刚 | Synergistic medicinal composition containing thiopronin and Chinese medicine extract |
| CN101810684A (en) * | 2010-04-27 | 2010-08-25 | 张大宇 | Synergic medicinal composition containing traditional Chinese medicine extract |
| CN101862378A (en) * | 2010-02-10 | 2010-10-20 | 李瑞菊 | Medicinal composition |
| CN1883585B (en) * | 2005-06-24 | 2011-01-12 | 江苏康缘药业股份有限公司 | Pharmaceutical composition for treating atherosclerosis and method for preparing same |
| CN102423346A (en) * | 2011-12-26 | 2012-04-25 | 云南白药中草药芯片有限公司 | Tree peony root bark extract, as well as preparation method and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427115C (en) * | 2005-08-19 | 2008-10-22 | 浙江大学 | Effective ingredients of Chinese medicine moutan bark and preparation method thereof |
| CN1981819B (en) * | 2005-12-14 | 2011-07-20 | 天津天士力制药股份有限公司 | Tree-peony root bark component, its preparation, making method and use |
-
2002
- 2002-11-26 CN CNB021386870A patent/CN1187069C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883585B (en) * | 2005-06-24 | 2011-01-12 | 江苏康缘药业股份有限公司 | Pharmaceutical composition for treating atherosclerosis and method for preparing same |
| CN100421688C (en) * | 2006-07-04 | 2008-10-01 | 刘海刚 | Synergistic medicinal composition containing thiopronin and Chinese medicine extract |
| CN100367986C (en) * | 2006-08-17 | 2008-02-13 | 陈乃车 | Cooperative drug comprising biphenyldicarboxylate |
| CN101862378A (en) * | 2010-02-10 | 2010-10-20 | 李瑞菊 | Medicinal composition |
| CN101810684A (en) * | 2010-04-27 | 2010-08-25 | 张大宇 | Synergic medicinal composition containing traditional Chinese medicine extract |
| CN101810684B (en) * | 2010-04-27 | 2011-08-31 | 李国� | Synergic medicinal composition containing traditional Chinese medicine extract |
| CN102423346A (en) * | 2011-12-26 | 2012-04-25 | 云南白药中草药芯片有限公司 | Tree peony root bark extract, as well as preparation method and application thereof |
| CN102423346B (en) * | 2011-12-26 | 2015-09-09 | 云南白药中草药芯片有限公司 | A kind of Cortex Moutan extract and its production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1187069C (en) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491611B (en) | Preparation method of serissa extract and use thereof | |
| CN102108090B (en) | Dihydroiso-coumarin glucoside compounds and preparation method and application thereof | |
| CN1187069C (en) | Method for extracting coxtex mouten total glucoside for treating hepatitis | |
| CN112645808A (en) | 5-hydroxy-1, 7-diphenyl-3-heptanone separated from galangal and application thereof | |
| CN102085223A (en) | Sweet osmanthus flower extractive as well as preparation method and application thereof to liver protection | |
| JP4106418B2 (en) | Herbal medicine composition for cartilage protection | |
| CN101011545A (en) | Method for extracting effective sites group of smilax China root | |
| CN1989984B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN1640885A (en) | Loguat leaf total dehydrocamphenilic acid and its preparation method and use | |
| CN1257720C (en) | Capsule of Chinese traditional medicine for treating thrombus | |
| CN104645015A (en) | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation | |
| CN108440472A (en) | The extraction separation method of sesquiterpene lactone constituents and protection liver and the drug for preventing Fatty Liver Disease in a kind of Artemisia capillaris | |
| CN113248483A (en) | Preparation method and application of lawn pennywort herb flavone glycoside monomer isovitexin | |
| CN1228052C (en) | Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN1131066C (en) | Application of radix scutellariae stem and leaf to pharmaceutical industry | |
| CN1277852A (en) | Pharmaceutical for preventing and treating senile dementia and depression, and its prepn. process | |
| CN1475254A (en) | Medicine for treating coronary disease and stenocardia and its preparation method | |
| CN100486600C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis | |
| CN1057300C (en) | Glucoside compound of catechine and preparation method and use thereof | |
| CN103864883B (en) | There is the triterpene saponin compound of liver protection function | |
| CN112472765B (en) | Preparation method of heat-clearing eight-ingredient extract | |
| CN116509921B (en) | Application of rice flower sesterterpene extract K01 in preparation of medicines for treating sepsis | |
| CN108409540B (en) | Compound for treating osteoarthritis and preparation and application thereof | |
| CN1401380A (en) | Anti-gout composition and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050202 Termination date: 20091228 |